Test for trisomy 21, quadruple test for trisomy 21, Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Test for trisomy 21

High-Risk Pregnancy? Consider a Non-Invasive Test For Trisomy 21

One crucial aspect of managing your high-risk pregnancy is ensuring that you screen for potential fetal anomalies and chromosomal disorders. As an alternative to invasive methods such as amniocentesis, Eurofins Biomnis offers tests for Trisomy 21 (Down Syndrome)that are entirely safe, offering expectant parents genuine peace of mind, from the first trimester. This NIPT (non-invasive prenatal testing) procedure draws from a simple maternal blood sample, and offers an accuracy rate of over 99%. By choosing a non-invasive test for trisomy 21, it can be safely determined whether the risk of fetal chromosomal disorders is high or low, potentially avoiding invasive sampling procedures that carry a small risk of losing the fetus.

Down Syndrome gets plenty of media attention as a relatively common fetal disorder, but many pregnant women remain unaware of all their options. Scheduling a quadruple test for trisomy 21 is an important step toward rule out risks for the common chromosomal anomalies. Non-invasive early genetic testing also allows expectant mothers at heightened risk of fetal abnormalities to undergo Patau Syndrome screening without the risks associated with invasive testing methods. Safe, reliable, and rapid, a prenatal Down syndromescreening includesa test for trisomy 21. It can be obtained by at-risk expectant mothers starting at the tenth week of pregnancy, and offers an accuracy rate that exceeds 99%.

To rule out common pregnancy risks, scheduling an NIPT procedure with a primary care physician or other healthcare provider offers patients a safer way to take a trisomy 21 screening test. The groundbreaking technology developed by Eurofins Biomnis consists in prenatal Down Syndrome screeningkits that can be ordered to your physician's practice and carried out there, or at aEurofins Biomnis partner laboratory. During your consultation, your healthcare provider will prescribe a NIPT and ask you to sign an informed consent form, which is mandatory for all genetic tests. The trisomy 21 screening test is rapid, and results for the test are generally available after 7 working days.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%